Fixed drug eruption related to ibuprofen presenting as giant bullae on the posterior thigh.

Fixed drug eruptions (FDEs), first described by Bourns in 1889, are solitary or multiple, sharply demarcated, round to oval, edematous and erythematous patches that arise after exposure to a specific medication. They can be pink to dark red to brown and can be larger than 10 cm in size. In almost a third of patients in some case series, these lesions have been reported to progress to vesicles or bullae.

A case of vemurafenib-induced keratosis pilaris-like eruption.

Vemurafenib, a selective BRAF kinase inhibitor, is a new anti-cancer drug recently proven to improve survival in patients with metastatic melanoma harboring the BRAF V600E mutation. BRAF is one of three RAF kinases (ARAF, BRAF, CRAF) involved in the MAP kinase pathway. Mutations in BRAF are reported to be present in 40 to 70 percent of melanomas and in lower frequencies in various other malignancies.

Unilateral multisegmental morphea.

There are 5 subtypes of morphea that are based on disease distribution and presentation, including plaque, localized, generalized, linear, and deep morphea. We report a case of a young patient with morphea lesions in scattered locations confined to 1 side of the body, which we have termed unilateral multisegmental morphea.

Denuded congenital lesions: recessive dystrophic epidermolysis bullosa.

Recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens type) (RDEB-HS) is a rare severe mechanobullous disorder resulting from a defect in collagen VII. Patients with RDEB-HS present with generalized blistering and denudation of the skin at birth and have mucosal involvement. The repeated blistering leads to scarring, which may be deforming and result in serious complications.